Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Oncogene. 2014 Sep 22;34(28):3662–3675. doi: 10.1038/onc.2014.297

Figure 8. Downregulation of NEDD9 expression via siNEDD9-Vivo-Morpholino treatment decreases tumor progression in xenograft model of breast cancer.

Figure 8

(a) WB analysis of WCL with anti-NEDD9 antibodies of moControl (moCon) or moNEDD9 MDA-MB-231 treated cells. (b) Representative images of bioluminescence (BLI) of mice orthotopically injected with MDA-MB-231LN cells after 1 weeks of treatment. (c) Quantification of the primary tumor growth based on BLI, n=4/group, mean total photon flux +/−S.E.M, t-test p=0.0266 after 1 weeks of treatment; (d) Quantification of mitotic cells in primary tumor +/−S.E.M after 1 weeks of treatment, n=4 in each group, t-test, p<0.0001; (e) Quantification of percentage of necrotic area in primary tumor +/−S.E.M after 1 weeks of treatment, n=4 in each group, p=0.0081.